Note: Descriptions are shown in the official language in which they were submitted.
CA 02503029 2008-07-07
PROCESS FOR SYNTHESIZING L-y-METHYLENE
GLUTAMIC ACID AND ANALOGS
FIELD OF THE INVENTION
This invention relates to a process for synthesizing substantially
enantiomerically pure
amino acids, and will have application to a synthetic process for synthesizing
the L-enantiomer
of glutamic acid and substituted analogs thereof.
BACKGROUND OF THE INVENTION
It is well known in biochemistry that all amino acids exist in two three
dimensional
forms, which are virtual mirror images of each other. The two forms are
referred to in the art by
the direction in which they rotate polarized light-levorotatory (L) and
dextrorotatory (D),
respectively left and right. Fischer representations of the structural
formulas for the two
enantiomers of glutamic acid are depicted below.
1
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
O NH2 ~0
HO-C-CH2-CH2-C-C
H OH
L-glutainic acid
O H 0
~
HO- C- CH2- CH2- C- C
I
NH2 ~OH
D-glutamic acid
It is also well known that the L-enantiomer is the naturally occurring form of
each amino acid found in nature. The L-enantiomer of each amino acid that
forms a
part of a drug agent is also the "active" enantiomer for medicinal purposes.
It is well known that antifolates which contain only the L-enantiomer of
glutamic acid are much more active than those which include the D-enantiomer
in a
racemic mixture of the two enantiomers. The pure D-enantiomer of MDAM, as with
most antifolates, is virtually inactive as a drug.
4' -methylene-4-[(2, 4-diamino-3 , 4-dihydropteridin-6-yl) ethyl] -benzoyl-
glutamic
acid, also referred to as 4-deoxy-4-amino-10-deazapteroyl- -methylene glutamic
acid,
and as -methylene-10-deazaaminopterin (MDAM) is a well-known investigational
antitumor agent. MDAM is currently undergoing human clinical trials in the
United
States and abroad as a treatment for cancer. MDAM and other antifolates are
essentially "two-part" molecules, with a pteroic acid part and an amino acid
part.
When L- -methylene-glutamic acid forms the amino acid part, the agent is known
as
L-MDAM.
2
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
-methylene-L-glutamic acid is also a well-known depolarizing agent in the rat
spinal cord. This property is suggestive of potent CNS activity, which may
translate
into the development of agents to treat various CNS disorders.
-methylene-L-glutamic acid has been isolated in substantially pure form from
germinated peanuts as described in US Patent 5,550,128. The free acid form of -
methylene-L-glutamic acid has been synthesized starting from L-pyroglutamic
acid, as
shown in the Ezquerra publication, appended to the Information Disclosure
Sheet that
accompanies this application.
-methylene-L-glutamic acid, which makes up the amino acid part of L-MDAM
has been previously synthesized, through a previously unpublished process from
a di-
protected L-pyroglutamate starting material. The pyroglutamate is available
commercially, and has also been synthesized by a previously unpublished
process.
SUMMARY OF THE INVENTION
This invention involves a process for synthesizing substantially pure L-amino
acids, as well as certain intermediate compounds. Primarily, the process of
this
invention will be used to synthesize substantially pure L-glutamic acid and
intermediate
compounds from which L-glutamic acid can be produced.
The process when employed to synthesize -methylene glutamic acid or an ester
thereof includes derivatizing pyroglutamic acid or an ester thereof to add a
methylene
moiety; then decyclization of the pyroglutamate to form the linear glutamic
acid or
ester.
3
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
Derivatization of the pyroglutamate is accomplished by first protecting the
nitrogen and carboxylic acid functional groups; then adding a -methylene
moiety
through a three-step procedure, which may be performed at or close to room
temperature, and that may optionally be carried out in a single vessel. The
preferred
process is depicted in detail in the following Detailed Description.
It is an object of this invention to provide for a simple and improved process
for
synthesizing substantially pure L-glutamic acid and the like.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The preferred embodiment herein described is not intended to be exhaustive or
to limit the invention to the precise reagents, reaction steps or conditions
disclosed. It
has been chosen and described to explain the principles of the invention, and
its
application and practical use to thereby enable others skilled in the art to
understand its
teachings.
The process of this invention has as its primary objective the synthesis of
substantially pure L-amino acids, most particularly the critical intermediate
compound
in the synthesis of the investigational anticancer drug, -methylene-10-
deazaaminopterin
(MDAM), whose structure is shown below:
NH2 0 COOH
N~ N CHZ- CH2 C-IN- CH
NHZ~ N I I~~ 4
~
COOH
L-MDAM
19
4
CA 02503029 2008-07-07
As stated previously, L-MDAM is synthesized from two critical intermediates:
(1) pteroic
acid; and (2) -methylene-L-glutamic acid. The two intermediates are coupled
via any of the
known processes, with one such process being disclosed in United States Patent
4,996,207. With
slight modifications in the reagents used, similar L-amino acids may be
synthesized by the
process of this invention.
The process for synthesizing -methylene-L-glutamic acid is depicted in Scheme
1. As
shown in Scheme 1, the process includes multiple steps in converting the
starting material, a
pyroglutamic acid derivative or an ester thereof, to the finished product,
substantially
enantiomerically pure -methylene-L-glutamic acid.
SCHEME 1
H
1
O N CO2H
PG PG
I 1 PG
PG O N,,,,-CO2PC1 O N.,..OCOZPGi 0 CO PG
O N ....CO2PGI ' ---- 2 ~
HO
Z 3 4
Scheme I illustrates the process of this invention as employed to synthesize 4-
methylene-
L-pyroglutamic acid 5. As shown, the preferred starting reagent is L-
pyroglutamic acid 1. The
process includes first protecting the nitrogen and carboxylic
5
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
acid functional moieties to produce the diprotected pyroglutamate 2, wherein
PG and
PGl are commonly known protecting groups for nitrogen and carboxylic acid,
respectively.
Protecting groups include specific moieties for protecting, in particular,
nitrogen (amino) terminal moieties and oxygen (carboxylic acid) terminal
moieties.
Protecting groups are well known in the art and are described in detail in
Kocienski,
P., Protecting Groups, Foundations of Organic Chemistry (Thieme, 1994); and
Greene, Wuts, Protective Groups in Organic Synthesis (Wiley, 2d ed. 1990), and
in
dozens of other reference publications.
Common protecting groups for nitrogen include t-butoxycarbonyl (t-BOC or
BOC), 9-fluorenyl-methoxy-carbonyl (FMOC) and others well known in. the
organic
synthesis arts. Common protecting groups for carboxylic acid include lower
alkyls,
tritnethylsilyl alkyls, and others well known in the organic synthesis arts.
Methods for
adding protecting groups were carried out using the well-known processes in
the
publications cited previously.
The protected pyroglutamate 2 is then converted to a 4-enamine 3, preferably
by reacting with an amide, or most preferably a nitrogen-containing acetal.
This
conversion is preferably carried out at elevated temperatures, between 70 C to
130 C,
most preferably between 105 C and 115 C. Enamine 3 is hydrolyzed, preferably
with
a strong acid, to the hydroxymethylene intermediate 4, then reduced in a basic
solution
to the desired product, the diprotected 4-methylene pyroglutamate 5. Detailed
process
steps and reagents, as well as preferred reaction conditions may be found in
the
specific examples, infra.
6
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
SCHEME 2
PG
I H
O N,,,, .C02PG1 10 C02H
HO2C NPG
6
H, ,, CO2H CO2R2
HO2C NH3}Cl" R102C NH3+Cl"
0 7 8
Scheme 2 illustrates the conversion of the 4-methylene pyroglutamate 5 to the
preferred final product, 4-methylene-L-glutamic acid, and certain salts and
esters
5 thereof (6-8). A strong base is first reacted with the pyroglutamate 5, and
is then
followed by acidification of the resultant mixture to effect the conversion to
the N-
protected linear L-glutamic acid derivative (L-Glu) 6. Protected L-Glu 6 is
deprotected
by a common procedure to form L-Glu salt 7, and the salt is then esterified to
produce
the final product (8). Rl and R2 are oxygen-protecting agents, preferably
lower (C1-C6)
alkyl moieties.
The esterified L-Glu salt 8 may be used in the synthesis of L-MDAM by a
coupling reaction of salt 8 to a pteroic acid derivative. The coupling
reaction can be
performed by any of a number of well-known procedures as outlined above.
The following specific examples illustrate the preferred process.
7
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
Example 1
Ethyl-(2S)-pyroglutamate
To a solution of L-pyroglutamic acid (5.0 g) in ethanol (150 ml) was added
98 % sulfuric acid (0.3 g). The resulting reaction mixture was stirred at room
temperature for 48 hours. Sodium carbonate (1.5 g) was added and the stirring
was
continued for an additional 1.5 hours. The suspension was filtered and the
filtrate was
evaporated under reduced pressure. To the residue was added methyl t-butyl
ether
(MTBE- 100 ml) and the resulting mixture was filtered. The filtrate was
evaporated
under reduced pressure to yield 6.5 g of the desired product as white solid.
Example 2
Ethyl-(2S)-N-(t-butoxycarbonyl)pyroglutamate
To a solution of ethyl L-pyroglutamate (1.6 g), di(t-butyl)dicarbonate (2.4 g)
and triethylamine (1.6 ml) in dichloromethane (7 ml) was added
dimethylaminopyridine
(DMAP- 61 mg). The resulting mixture was stirred at room temperature
overnight.
The volatiles were removed under reduced pressure and the residue was taken up
in
MTBE (7 ml). The solid was removed by filtration and washed with fresh MTBE.
The combined filtrates were washed with water (3 ml) and acidified to pH 3
with 1:9
v/v of dilute HCI. The resulting solution was washed with more water (2 x 3
ml). The
organic phase was dried over sodium sulfate and activated carbon, filtered and
evaporated under reduced pressure. The crude product was recrystallized from
ether-
hexanes to yield 1.65 g of product as white needles.
8
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
Example 3
Ethyl-(2S)-4-(N, N-dimethylaminomethylidene)-N 1-(t-
butoxycarbonyl)pyroglutamate
A mixture of Ethyl (2S)-N-(tert-butoxycarbonyl)pyroglutamate (125 g, 486
mmol) and N, N-dimethyl formamide diisopropyl acetal (125 g, 713 mmol) was
heated
at 105-115 C for 21 hrs. Another portion of N, N dimethyl formamide
diisopropyl
acetal (25 g, 143 mmol) was added and the solution was heated at 105-115 C for
another 4 hrs. The solution was concentrated under reduced pressure at 70 C
and
dried at 70 C/ 0.3 mmHg until there is no bubbling. Crystallization from
methyl t-
butyl ether (250 ml) gave the named product as a white crystal (97 g, 64%): 1H
NMR
(300Hz, CDC13) 7.06(t, 1H, J = 1.8 Hz), 4.46 (dd, 1H, J = 3.9, 10.5 Hz), 4.22 -
4.08 (m, 2 H), 3.32 - 3.14 (m, 1 H), 2.95 (s, 6 H), 2.89 - 2.78 (m, 1 H), 1.43
(s, 9
H), 1.21 (t, 3 H, J = 7.2 Hz).
For this example, it is recommended to use 2 equivalents of N, N-dimethyl
formamide diisopropyl acetal to each equivalent of pyroglutamate at the
beginning.
After 21 hrs of heating, Another 0.2 equivalent of N, N-dimethyl formamide
diisopropyl acetal can be added if an HPLC analysis shows that the amount of
starting
material is great than 1.5 %.
Example 4
Ethyl-(2S)-4-methylene-N 1-(t-butoxycarbonyl)pyroglutamate
To a solution of ethyl (2S)-N-(t-butoxycarbonyl)-4-(dimethylaminomethylidene)
9
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
pyroglutamate (100 g, 320.1 mmol) in tetrahydrofuran (THF- 500 ml) was added 1
N
HCl (352 ml). The mixture was stirred for 2 hours at room temperature. After
separation, the organic layer was added potassium carbonate (62 g) and 37 %
formaldehyde (310 ml). The resulting solution was stirred at room temperature
for 45
minutes, and the aqueous layer was separated. The organic layer was
concentrated and
the residue was taken up in MTBE (1000 ml). The resulting mixture was washed
with
water (380 ml), 20% Na2SO3 (380 ml) and water (380 ml), dried (MgSO4) and
evaporated to dryness in vacuo to yield the title product (71.7 g) as light
yellow oil.
This crude material was used as is in the next step.
Example 5
4-methylene-N-(t-butoxycarbonyl)-L-glutamic acid
The crude product from Example 4 was dissolved in THF (650 ml) and to this
solution was slowly added 2M LiOH (425 ml). The resulting mixture was stirred
at
room temperature for 48 hours. The aqueous layer was separated, acidified to
pH 2
with 2N HCI, and extracted with ethyl acetate (2 x 500 ml). The extract was
washed
with water (250 ml) and dried (MgSO4). The dried solution was used directly in
the
next step.
10
CA 02503029 2005-04-19
WO 2004/039314 PCT/US2003/033236
Example 6
4-methylene-L-glutamic acid hydrochloride
To the dried solution from Example 4 was bubbled HCl (32.5 g over a period
of 1 hour). The stirring was continued for an additional 1.5 hours after HCl
was
stopped. The resulting white solid was filtered, washed with MTBE (100 ml) and
dried in vacuo to yield 31 g of substantially pure (> 99 %) of the title
compound.
Example 7
Diethyl 4-methylene-L-glutamate hydrochloride
4-Methylene L-glutamic acid hydrochloride (31 g) from Example 6 was
dissolved in ethanol (310 ml). Thionyl chloride (31 ml) was added dropwise.
The
resulting mixture was stirred at room temperature overnight and then refluxed
for 2.5
hours. The reaction mixture was concentrated to dryness. The crude product was
dissolved in hot ethanol (31 ml) and to the hot solution was added anhydrous
MTBE
(620 ml). The resulting mixture was kept at room temperature overnight. The
crystals
of the product were filtered and dried in vacuo to yield 34 g of substantially
pure
(> 99 %) title compound. The enantiomeric purity of the final product is 99.5
% as
verified in a chiral AGP column, 4mM PBS (pH 6), isopropanol = 98.5:1.5.
11
